Latest News for: jcr

Edit

EGCO achieves “A” credit rating with “Stable” outlook from JCR reflecting strong business and financial fundamentals (EGCO - Electricity Generating pcl)

Public Technologies 26 Dec 2025
(JCR), one of Japan's leading credit rating agencies ... JCR considers EGCO's rating to be equivalent to the group's creditworthiness, given its control over subsidiaries and JVs, its central role in group strategy and funding.
Edit

Italfarmaco and JCR Pharmaceuticals Announce Commercialisation Agreement for Givinostat in Japan and Strategic Collaboration in ...

Rutland Herald 24 Dec 2025
MILAN & HYOGO, Japan--(BUSINESS WIRE)--Dec 24, 2025-- ....
Edit

Notice Concerning Upgrade of Long-Term Issuer Rating by Japan Credit Rating Agency (JCR) (SKY Perfect JSAT Holdings Inc)

Public Technologies 28 Nov 2025
Notice Concerning Upgrade of Long-Term Issuer Rating by Japan Credit Rating Agency (JCR) ... (JCR) has upgraded our long-term issuer rating today ... (JCR) ３．Announced Date ... For more detailed information, please refer to the JCR's website.
Edit

FY2025 Second Quarter Results Briefing Session - Script（1,455KB） (JCR Pharmaceuticals Co Ltd)

Public Technologies 04 Nov 2025
JCR Pharmaceuticals Co., Ltd ... [Company Name] JCR Pharmaceuticals Co., Ltd ... Anne Bechet Senior Executive Officer, Executive Director, Development Division, JCR Europe B.V. General Manager, JCR USA Inc ... JCR Pharmaceuticals Co.
Edit

FY2025 Second Quarter Results Briefing Session - Material（1,550KB） (JCR Pharmaceuticals Co Ltd)

Public Technologies 30 Oct 2025
JCR Pharmaceuticals Co., Ltd ... Infusion [JCR] remained aligned with the supply plans of Sumitomo Pharma Co., Ltd ... [JCR] ... [JCR] ... Infusion [JCR] ... Infusion [JCR] ... Executive Director, Development Division General Manager, JCR Europe B.V ... Jcr ... JCR ... [JCR] ... [JCR].
Edit

FY2025-Q2 Financial Report (Jul. 1-Sep. 30, 2025)（536KB） (JCR Pharmaceuticals Co Ltd)

Public Technologies 30 Oct 2025
JCR Pharmaceuticals Co., Ltd ... [JCR] Darbepoetin Alfa BS Inj. [JCR] ... Infusion [JCR] ... In addition to expanding the applicability of JCR's proprietary J-Brain Cargo®technology to various modalities, we are focusing on licensing-out of this technology.
Edit

BADEA’s “AAA” Credit Rating Affirmed by the Japan Credit Rating Agency (JCR) (Arab Bank for Economic Development in Africa)

Public Technologies 09 Oct 2025
BADEA'S "AAA" CREDIT RATING AFFIRMED BY THE JAPAN CREDIT RATING AGENCY (JCR) ... Japan Credit Rating Agency (JCR) has reaffirmed the AAA long-term issuer rating of the Arab Bank for Economic Development in Africa (BADEA), with a Stable outlook.
Edit

JCR Pharmaceuticals Enhances Delivery of AAV Gene Therapy to Central Nervous System and Muscle with ...

Business Wire 08 Oct 2025
HYOGO, Japan--(BUSINESS WIRE)--JCR presented non-clinical data that demonstrate the ability of its proprietary JUST-AAV platform to achieve efficient delivery of AAV gene therapy ... .
Edit

JCR Pharmaceuticals Enhances Delivery of AAV Gene Therapy to Central Nervous System and Muscle with Novel Capsid Engineering Platform Technology

Pharmiweb 07 Oct 2025
-Oral Presentation at ESGCT Highlights Potential of JCR’s Proprietary JUST-AAV Platform to Facilitate More Efficient Delivery While Reducing Liver Tropism-. HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd ... JCR Pharmaceuticals Co., Ltd.
Edit

JCR Pharmaceuticals Announces Licensing Agreement with Menagen to Commercialize Agalsidase Beta BS I.V. Infusion [JCR] ...

Business Wire 02 Oct 2025
HYOGO, Japan--(BUSINESS WIRE)--JCR announced an exclusive licensing agreement with Menagen to commercialize Agalsidase Beta BS I.V. Infusion [JCR] across nine MENAT markets ... .
Edit

JCR Pharmaceuticals to Present at the European Society of Gene and Cell Therapy (ESGCT) 32nd ...

Business Wire 01 Oct 2025
HYOGO, Japan--(BUSINESS WIRE)--JCR will present non-clinical data from its novel JUST-AAV gene therapy platform technology in an oral session at the ESGCT 32nd Annual Congress ... .
Edit

JCR Pharmaceuticals Announces Licensing Agreement with Menagen to Commercialize Agalsidase Beta BS I.V. Infusion [JCR] Across Nine MENAT Markets

Pharmiweb 01 Oct 2025
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd ... Infusion [JCR] (the “product”) upon approval across nine MENAT markets ... Following local approvals, JCR will supply the product, and Menagen will lead commercialization in the region.
Edit

Integrated Report 2025（8,332KB） (JCR Pharmaceuticals Co Ltd)

Public Technologies 26 Sep 2025
). The text version of this document is not available ... JCR Pharmaceuticals Co.
Edit

JCR Pharmaceuticals and Alexion Achieve Milestone in Collaborative Neurodegenerative Disease Program

Business Wire 19 Sep 2025
HYOGO, Japan--(BUSINESS WIRE)--JCR announced that is has achieved a key research milestone in one of its collaborative programs with Alexion, AstraZeneca Rare Disease ... .
Edit

Philippine economic outlook steady – JCR

The Philippine Star 18 Sep 2025
The Philippine economy remains resilient on the back of strong growth, easing inflation and fiscal consolidation efforts under the Marcos administration, according to Japan Credit Rating Agency ....

Article Search

tools
×
×
×
×